California Supreme Court
Jun. 14, 2016
State high court to weigh if drugmaker is liable for generic drug's harm
The state Supreme Court will review whether the makers of brand-name pharmaceuticals can be sued for failing to warn of a drug's defects when a generic version of a brand-name drug allegedly caused injury.
Daily Journal Staff Writer
The state Supreme Court will review whether the makers of brand-name pharmaceuticals can be sued for failing to warn of a drug's defects when it was a generic version of a brand-name drug that allegedly caused injury.
Novartis Pharmaceuticals Corp. has asked the high court to be absolved of liability from harm allegedly sustained by twin minors in utero when their mother consumed generic versions ...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In